Company news
Herantis Pharma Plc (OMXHEX:HRTIS) news
Herantis Pharma Plc news releases on 6ix. Latest, Aug 10, 2026: Herantis Pharma Oyj : to publish financial statements for the first half of 2026 on August 20…
Press releases & updates
Herantis Pharma Oyj : to publish financial statements for the first half of 2026 on August 20, 2026 - invitation to webcast presentation
August 10, 2026
Herantis Pharma Oyj : to publish financial statements for the first half of 2026 on August 20, 2026 – invitation to webcast presentation
August 10, 2026
Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
June 25, 2026
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
June 2, 2026
Herantis Pharma Oyj : reports positive FDA feedback and finalizes Phase 2a study design for HER-096
June 2, 2026
Herantis Pharma Oyj : Plc Annual Report 2025
March 30, 2026
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases
March 16, 2026
Herantis Pharma releases 2H and FY 2025 report today
March 5, 2026
Herantis Pharma Oyj : to publish financial statements 2025 on 5 March 2026 – invitation to webcast presentation
February 23, 2026
Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096
February 19, 2026
Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease
January 7, 2026
Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096
November 26, 2025
Herantis Pharma presents positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease
October 7, 2025
Herantis Pharma releases 1H 2025 report today
August 21, 2025
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease
August 14, 2025
Herantis Pharma Oyj : Plc's board decides on new option rights program for managing director, management team and other key personnel
May 23, 2025
First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease
May 13, 2025
Herantis Pharma Oyj : Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders and constitutive meeting of the Board of Directors
April 23, 2025